Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Alimera (ALIM) just unveiled an announcement.
Alimera Sciences, Inc. has entered into a definitive Merger Agreement with ANI Pharmaceuticals, Inc., under which Alimera will merge with ANI’s subsidiary and become a wholly owned indirect subsidiary of ANI. Shareholders of Alimera will receive $5.50 in cash and one contingent value right per share, which entitles them to additional payments based on future revenue milestones. The merger is contingent upon customary closing conditions, including regulatory approvals and a majority shareholder vote. Additionally, significant shareholders have entered a Voting Agreement to support the merger, and debt financing has been secured for the transaction.
Find detailed analytics on ALIM stock on TipRanks’ Stock Analysis page.
